Oncology biosimilars — including rituximab, trastuzumab, bevacizumab, and checkpoint inhibitor biosimilars in development — represent the highest-value biosimilar market segment with enormous potential cost savings in cancer treatment, with the Biosimilars Market reflecting oncology as the most commercially significant biosimilar frontier.
Trastuzumab biosimilar market...
0 Comments
0 Shares
323 Views
0 Reviews
Sponsored
×
Install Ework Face
Install our app for a better experience, faster access, and offline capabilities.
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
